These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30857829)

  • 1. Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain.
    Dai J; Chen A; Zhu M; Qi X; Tang W; Liu M; Li D; Gu Q; Li J
    Biochem Pharmacol; 2019 May; 163():404-415. PubMed ID: 30857829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
    Donnelly A; Blagg BS
    Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone.
    Marcu MG; Chadli A; Bouhouche I; Catelli M; Neckers LM
    J Biol Chem; 2000 Nov; 275(47):37181-6. PubMed ID: 10945979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
    Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
    Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fungal mycotoxin penisuloxazin A, a novel C-terminal Hsp90 inhibitor and characteristics of its analogues on Hsp90 function related to binding sites.
    Dai J; Zhu M; Qi X; Wang Y; Li H; Tang S; Wang Q; Chen A; Liu M; Gu Q; Li D; Li J
    Biochem Pharmacol; 2020 Dec; 182():114218. PubMed ID: 32949584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of epipolythiodioxopiperazines HDN-1 and chaetocin as novel inhibitor of heat shock protein 90.
    Song X; Zhao Z; Qi X; Tang S; Wang Q; Zhu T; Gu Q; Liu M; Li J
    Oncotarget; 2015 Mar; 6(7):5263-74. PubMed ID: 25742791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
    Garg G; Khandelwal A; Blagg BS
    Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization.
    Allan RK; Mok D; Ward BK; Ratajczak T
    J Biol Chem; 2006 Mar; 281(11):7161-71. PubMed ID: 16421106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
    Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
    Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification.
    Li L; Chen N; Xia D; Xu S; Dai W; Tong Y; Wang L; Jiang Z; You Q; Xu X
    Cell Chem Biol; 2021 Oct; 28(10):1446-1459.e6. PubMed ID: 33932325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative approaches to Hsp90 modulation for the treatment of cancer.
    Hall JA; Forsberg LK; Blagg BS
    Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
    Bickel D; Gohlke H
    Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors.
    Jiang F; Guo AP; Xu JC; Wang HJ; Mo XF; You QD; Xu XL
    Eur J Med Chem; 2017 Dec; 141():1-14. PubMed ID: 29028527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket.
    Söti C; Rácz A; Csermely P
    J Biol Chem; 2002 Mar; 277(9):7066-75. PubMed ID: 11751878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
    Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hydrophobic segment within the C-terminal domain is essential for both client-binding and dimer formation of the HSP90-family molecular chaperone.
    Yamada S; Ono T; Mizuno A; Nemoto TK
    Eur J Biochem; 2003 Jan; 270(1):146-54. PubMed ID: 12492485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.
    Moses MA; Henry EC; Ricke WA; Gasiewicz TA
    Cancer Prev Res (Phila); 2015 Mar; 8(3):249-57. PubMed ID: 25604133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
    Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH
    Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation.
    Cuyàs E; Verdura S; Micol V; Joven J; Bosch-Barrera J; Encinar JA; Menendez JA
    Food Chem Toxicol; 2019 Oct; 132():110645. PubMed ID: 31254591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
    Dutta Gupta S; Bommaka MK; Banerjee A
    Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.